#### Mayo Stratification of Myeloma and Risk-Adapated Therapy.

<table>
  <tr>
    <th> Standard risk(60%) </th>
    <th> Intermediate risk (20%) </th>
    <th> High risk (20%) </th>
  </tr>
  <tr>
    <td>t(11;14)</td>
    <td>t(4;14)</td>
    <td>Del 17p</td>
  </tr>
  <tr>
    <td> t(6;14) </td>
    <td> Del 13 </td>
    <td> t(14;16) </td>
  </tr>
  <tr>
    <td> Hyperdiploid </td>
    <td> Hypodiploid </td>
    <td> t(14;20) </td>
  </tr>
  <tr>
    <td> All Others </td>
    <td></td>
    <td>GEP  high-risk signature </td>
  </tr>
  <tr>
    <td> OS:  8-10 years </td>
    <td> OS:  4-5 years </td>
    <td> OS:  3years </td>
  </tr>
  <tr>
    <td colspan="3"> GEP, gene expression profiling; OS, overall survival<br>  </td>
  </tr>
</table>

#### The comprehensive Cytogenetic Scoring System (CCSS) for myelodysplastic syndromes.

| Prognostic subgroup | Defining cytogenetic abnormalities  |
| ------------------- | ----------------------- |
| Very good           | Loss of Y chromosome <br/>Del(11q)     |
| Good                | Normal <br/>del(5q) <br/>del(12p) <br/>del(20q) <br/>Double, including del(5q)      |
| Intermediate        | del(7q)<br/> Gain of chromosome 8 <br/>Gain of chromosome 19<br/> Isochromosome 17q <br/>Single or double abnormalities not specified in other subgroups <br/> Two or more independent non-complex clones |
| Poor                | Loss of chromosome 7<br/> inv(3), t(3q) or del(3q) <br/>Double including loss of chromosome 7 or del(7q) <br/>Complex (3 abnormalities)  |
| Very poor           | Complex (>3 abnormaliteis)    |
